Molnupiravir: Difference between revisions
(Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: *Common Trade Names: ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== ===Drug pregnan...") |
No edit summary |
||
| Line 6: | Line 6: | ||
==Adult Dosing== | ==Adult Dosing== | ||
===[[COVID]]=== | |||
* 800 mg q12hr x 5d | |||
* Ages 18 and older only, mild to moderate disease only | |||
* Within 5 days of symptom onset | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
| Line 13: | Line 16: | ||
==Special Populations== | ==Special Populations== | ||
===[[Drug pregnancy categories|Pregnancy Rating]]=== | ===[[Drug pregnancy categories|Pregnancy Rating]]=== | ||
* | *Avoid in pregnant or young patients given concern for mutagenicity | ||
===Lactation risk=== | ===Lactation risk=== | ||
| Line 45: | Line 48: | ||
==Comments== | ==Comments== | ||
* Phase 3 trial showed 30% reduction in risk of hospitalization or death | |||
==See Also== | ==See Also== | ||
Latest revision as of 20:32, 18 January 2022
Administration
- Type:
- Dosage Forms:
- Routes of Administration:
- Common Trade Names:
Adult Dosing
COVID
- 800 mg q12hr x 5d
- Ages 18 and older only, mild to moderate disease only
- Within 5 days of symptom onset
Pediatric Dosing
Special Populations
Pregnancy Rating
- Avoid in pregnant or young patients given concern for mutagenicity
Lactation risk
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
Mechanism of Action
Comments
- Phase 3 trial showed 30% reduction in risk of hospitalization or death